First Coast Mohs has been acquired by AQUA Dermatology
Dermatology and skin cancer specialist First Coast Mohs has partnered with AQUA Dermatology.
First Coast Mohs offers Mohs surgery, surgical and medical dermatology, dermatopathology, cosmetic and laser treatments, electrolysis and other aesthetic services from four state-of-the-art facilities in metro Jacksonville, Florida. The practice features seven clinicians, including two Mohs surgeons, two board certified dermatologists and three Advanced Practice Providers. First Coast Mohs was founded in 2002 by Dr. Scott Warren, who will continue to lead the practice following the transaction.
AQUA Dermatology, backed by Gryphon Investors and GTCR, is the largest dermatology practice in the southeastern United States with over 110 locations and 250 providers. For more than 25 years, the company has treated patients of all ages suffering from skin diseases, acne, sun damage, skin cancer and vein health issues, as well as those seeking cosmetic and plastic surgery. With First Coast Mohs, AQUA Dermatology now has 78 locations in Florida.
Oaklins Heritage in Jacksonville served as the intermediary and exclusive financial advisor to the seller in this transaction.
Dr. Scott Warren
Owner, First Coast Mohs
Sprechen Sie mit dem Deal Team
Daniel Edelman
Oaklins Heritage
Alex Kellison
Oaklins Heritage
Mike Bouton
Oaklins Heritage
Transaktionen
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Mehr erfahrenRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Mehr erfahrenDie Lindenhofgruppe veräussert ihre Mehrheitsbeteiligung an der LabPoint an Affidea Switzerland
Die LabPoint Medizinische Laboratorien AG wurde von Affidea Switzerland AG übernommen. Mit Affidea hat die Lindenhofgruppe AG einen starken strategischen Partner für die Weiterentwicklung der LabPoint gewonnen. Die Lindenhofgruppe bleibt bedeutende Aktionärin und Grosskundin des Unternehmens. Damit schafft sie die Grundlage für eine nachhaltige Weiterentwicklung von LabPoint unter einer neuen Ankeraktionärin. LabPoint soll ihre Position in der Labordiagnostik weiter stärken und gezielt ausbauen.
Mehr erfahren